{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:32:09Z","timestamp":1794313929417,"version":"4.9.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81773780"],"award-info":[{"award-number":["No. 81773780"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81973365"],"award-info":[{"award-number":["No.81973365"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81773216"],"award-info":[{"award-number":["No. 81773216"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82073320"],"award-info":[{"award-number":["No. 82073320"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["No.2019CFB650"],"award-info":[{"award-number":["No.2019CFB650"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lung cancer is a kind of malignancy with high morbidity and mortality worldwide. Paclitaxel (PTX) is the main treatment for non-small cell lung cancer (NSCLC), and resistance to PTX seriously affects the survival of patients. However, the underlying mechanism and potential reversing strategy need to be further explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified ALDH2 as a PTX resistance-related gene using gene microarray analysis. Subsequently, a series of functional analysis in cell lines, patient samples and xenograft models were performed to explore the functional role, clinical significance and the aberrant regulation mechanism of ALDH2 in PTX resistance of NSCLC. Furthermore, the pharmacological agents targeting ALDH2 and epigenetic enzyme were used to investigate the diverse reversing strategy against PTX resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Upregulation of ALDH2 expression is highly associated with resistance to PTX using in vitro and in vivo analyses of NSCLC cells along with clinicopathological analyses of NSCLC patients. ALDH2-overexpressing NSCLC cells exhibited significantly reduced PTX sensitivity and increased biological characteristics of malignancy in vitro and tumor growth and metastasis in vivo. EHMT2 (euchromatic histone lysine methyltransferase 2) inhibition and NFYA (nuclear transcription factor Y subunit alpha) overexpression had a cooperative effect on the regulation of ALDH2. Mechanistically, ALDH2 overexpression activated the RAS\/RAF oncogenic pathway. NSCLC\/PTX cells re-acquired sensitivity to PTX in vivo and in vitro when ALDH2 was inhibited by pharmacological agents, including the ALDH2 inhibitors Daidzin (DZN)\/Disulfiram (DSF) and JIB04, which reverses the effect of EHMT2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that ALDH2 status can help predict patient response to PTX therapy and ALDH2 inhibition may be a promising strategy to overcome PTX resistance in the clinic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-022-01579-9","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T06:03:03Z","timestamp":1651039383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["An EHMT2\/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Wenjing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"issue":"6","key":"1579_CR1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"1579_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","volume":"83","author":"JR Molina","year":"2008","unstructured":"Molina JR, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584\u201394.","journal-title":"Mayo Clin Proc"},{"key":"1579_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.omtn.2019.06.017","volume":"17","author":"W Liu","year":"2019","unstructured":"Liu W, et al. CS-PEI\/Beclin-siRNA downregulate multidrug resistance proteins and increase paclitaxel therapeutic efficacy against NSCLC. Mol Ther Nucleic Acids. 2019;17:477\u201390.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"10","key":"1579_CR4","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1158\/0008-5472.CAN-10-3623","volume":"71","author":"EA Hopper-Borge","year":"2011","unstructured":"Hopper-Borge EA, et al. Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-\/-) mice. Cancer Res. 2011;71(10):3649\u201357.","journal-title":"Cancer Res"},{"issue":"7","key":"1579_CR5","doi-asserted-by":"publisher","first-page":"478","DOI":"10.18632\/oncoscience.56","volume":"1","author":"JJ Hendrikx","year":"2014","unstructured":"Hendrikx JJ, et al. P-gp and taxanes. Oncoscience. 2014;1(7):478\u20139.","journal-title":"Oncoscience"},{"issue":"6","key":"1579_CR6","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.1999.17.6.1786","volume":"17","author":"M Monz\u00f3","year":"1999","unstructured":"Monz\u00f3 M, et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol. 1999;17(6):1786\u201393.","journal-title":"J Clin Oncol"},{"issue":"20","key":"1579_CR7","doi-asserted-by":"publisher","first-page":"11737","DOI":"10.1073\/pnas.191388598","volume":"98","author":"A Gon\u00e7alves","year":"2001","unstructured":"Gon\u00e7alves A, et al. Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci U S A. 2001;98(20):11737\u201342.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"47","key":"1579_CR8","doi-asserted-by":"publisher","first-page":"7280","DOI":"10.1038\/sj.onc.1206934","volume":"22","author":"GA Orr","year":"2003","unstructured":"Orr GA, et al. Mechanisms of Taxol resistance related to microtubules. Oncogene. 2003;22(47):7280\u201395.","journal-title":"Oncogene"},{"issue":"1","key":"1579_CR9","doi-asserted-by":"publisher","first-page":"874","DOI":"10.2119\/molmed.2011.00230","volume":"18","author":"R Wang","year":"2012","unstructured":"Wang R, et al. Identification of ING4 (inhibitor of growth 4) as a modulator of docetaxel sensitivity in human lung adenocarcinoma. Mol Med. 2012;18(1):874\u201386.","journal-title":"Mol Med"},{"issue":"5","key":"1579_CR10","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.3892\/or.2014.3433","volume":"32","author":"F Xiang","year":"2014","unstructured":"Xiang F, et al. MyD88 expression is associated with paclitaxel resistance in lung cancer A549 cells. Oncol Rep. 2014;32(5):1837\u201344.","journal-title":"Oncol Rep"},{"issue":"2","key":"1579_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cellsig.2014.11.023","volume":"27","author":"A Chatterjee","year":"2015","unstructured":"Chatterjee A, et al. MiR-16 targets Bcl-2 in paclitaxel-resistant lung cancer cells and overexpression of miR-16 along with miR-17 causes unprecedented sensitivity by simultaneously modulating autophagy and apoptosis. Cell Signal. 2015;27(2):189\u2013203.","journal-title":"Cell Signal"},{"issue":"8","key":"1579_CR12","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00109-017-1539-z","volume":"95","author":"X Xu","year":"2017","unstructured":"Xu X, et al. miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression. J Mol Med (Berl). 2017;95(8):861\u201371.","journal-title":"J Mol Med (Berl)"},{"issue":"7","key":"1579_CR13","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.trecan.2020.02.003","volume":"6","author":"J Cao","year":"2020","unstructured":"Cao J, et al. Cancer Epigenetics, Tumor Immunity, and Immunotherapy. Trends Cancer. 2020;6(7):580\u201392.","journal-title":"Trends Cancer"},{"issue":"8","key":"1579_CR14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrg.2016.59","volume":"17","author":"CD Allis","year":"2016","unstructured":"Allis CD, et al. The molecular hallmarks of epigenetic control. Nat Rev Genet. 2016;17(8):487\u2013500.","journal-title":"Nat Rev Genet"},{"key":"1579_CR15","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.1038\/ncomms6792","volume":"5","author":"S Suzuki","year":"2014","unstructured":"Suzuki S, et al. Prediction of antibiotic resistance by gene expression profiles. Nat Commun. 2014;5:5792.","journal-title":"Nat Commun"},{"issue":"1","key":"1579_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/annonc\/mdh006","volume":"15","author":"T Kurata","year":"2004","unstructured":"Kurata T, et al. Effect of re-treatment with gefitinib (\u201cIressa\u201d, ZD1839) after acquisition of resistance. Ann Oncol. 2004;15(1):173\u20134.","journal-title":"Ann Oncol"},{"issue":"2","key":"1579_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/ijgc-00009577-200503000-00004","volume":"15","author":"HT See","year":"2005","unstructured":"See HT, et al. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer. 2005;15(2):209\u201316.","journal-title":"Int J Gynecol Cancer"},{"issue":"19","key":"1579_CR18","doi-asserted-by":"publisher","first-page":"8721","DOI":"10.7150\/thno.41648","volume":"10","author":"T Huang","year":"2020","unstructured":"Huang T, et al. Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics. 2020;10(19):8721\u201343.","journal-title":"Theranostics"},{"issue":"1","key":"1579_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12943-020-01256-9","volume":"19","author":"W Wang","year":"2020","unstructured":"Wang W, et al. Characterization of a novel HDAC\/RXR\/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. Mol Cancer. 2020;19(1):134.","journal-title":"Mol Cancer"},{"key":"1579_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cbi.2014.10.028","volume":"234","author":"CA Morgan","year":"2015","unstructured":"Morgan CA, et al. Development of a high-throughput in vitro assay to identify selective inhibitors for human ALDH1A1. Chem Biol Interact. 2015;234:29\u201337.","journal-title":"Chem Biol Interact"},{"issue":"3","key":"1579_CR21","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1124\/pr.111.005538","volume":"64","author":"V Koppaka","year":"2012","unstructured":"Koppaka V, et al. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacol Rev. 2012;64(3):520\u201339.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"1579_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physrev.00017.2013","volume":"94","author":"CH Chen","year":"2014","unstructured":"Chen CH, et al. Targeting aldehyde dehydrogenase 2: new therapeutic opportunities. Physiol Rev. 2014;94(1):1\u201334.","journal-title":"Physiol Rev"},{"issue":"4","key":"1579_CR23","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1158\/1535-7163.MCT-18-1167","volume":"18","author":"G Kallifatidis","year":"2019","unstructured":"Kallifatidis G, et al. \u03b2-Arrestins regulate stem cell-like phenotype and response to chemotherapy in bladder cancer. Mol Cancer Ther. 2019;18(4):801\u201311.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1579_CR24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cbi.2011.10.007","volume":"195","author":"JS Moreb","year":"2012","unstructured":"Moreb JS, et al. The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance. Chem Biol Interact. 2012;195(1):52\u201360.","journal-title":"Chem Biol Interact"},{"issue":"11","key":"1579_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0242809","volume":"15","author":"B Yuan","year":"2020","unstructured":"Yuan B, et al. Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype and enhance therapy resistance in AML through a TGF-\u03b2-p38-ALDH2 pathway. PLoS ONE. 2020;15(11): e0242809.","journal-title":"PLoS ONE"},{"issue":"36","key":"1579_CR26","doi-asserted-by":"publisher","first-page":"58516","DOI":"10.18632\/oncotarget.11305","volume":"7","author":"X Liu","year":"2016","unstructured":"Liu X, et al. Targeting ALDH1A1 by disulfiram\/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells. Oncotarget. 2016;7(36):58516\u201330.","journal-title":"Oncotarget"},{"issue":"2","key":"1579_CR27","first-page":"42","volume":"44","author":"MJ Stewart","year":"1996","unstructured":"Stewart MJ, et al. Distribution of messenger RNAs for aldehyde dehydrogenase 1, aldehyde dehydrogenase 2, and aldehyde dehydrogenase 5 in human tissues. J Investig Med. 1996;44(2):42\u20136.","journal-title":"J Investig Med"},{"issue":"1","key":"1579_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1006\/abbi.2001.2713","volume":"398","author":"M You","year":"2002","unstructured":"You M, et al. Transcriptional control of the human aldehyde dehydrogenase 2 promoter by hepatocyte nuclear factor 4: inhibition by cyclic AMP and COUP transcription factors. Arch Biochem Biophys. 2002;398(1):79\u201386.","journal-title":"Arch Biochem Biophys"},{"key":"1579_CR29","doi-asserted-by":"publisher","first-page":"15337","DOI":"10.1038\/ncomms15337","volume":"8","author":"YH Gao","year":"2017","unstructured":"Gao YH, et al. VHL deficiency augments anthracycline sensitivity of clear cell renal cell carcinomas by down-regulating ALDH2. Nat Commun. 2017;8:15337.","journal-title":"Nat Commun"},{"issue":"7","key":"1579_CR30","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/ncb1005","volume":"5","author":"LA Allan","year":"2003","unstructured":"Allan LA, et al. Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol. 2003;5(7):647\u201354.","journal-title":"Nat Cell Biol"},{"issue":"6","key":"1579_CR31","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.ccell.2017.11.003","volume":"32","author":"R Pan","year":"2017","unstructured":"Pan R, et al. Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer Cell. 2017;32(6):748-60.e6.","journal-title":"Cancer Cell"},{"issue":"28","key":"1579_CR32","doi-asserted-by":"publisher","first-page":"45249","DOI":"10.18632\/oncotarget.16902","volume":"8","author":"H Wang","year":"2017","unstructured":"Wang H, et al. ERK expression and its correlation with STAT1 in esophageal squamous cell carcinoma. Oncotarget. 2017;8(28):45249\u201358.","journal-title":"Oncotarget"},{"issue":"1","key":"1579_CR33","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1080\/21691401.2019.1669616","volume":"47","author":"D Ma","year":"2019","unstructured":"Ma D, et al. PLCG2 promotes hepatocyte proliferation in vitro via NF-\u03baB and ERK pathway by targeting bcl2, myc and ccnd1. Artif Cells Nanomed Biotechnol. 2019;47(1):3786\u201392.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"1579_CR34","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ebiom.2018.11.045","volume":"40","author":"C Rodriguez-Aguayo","year":"2019","unstructured":"Rodriguez-Aguayo C, et al. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK\/Erk-ETS1-ELK1\/CFTR1 axis. EBioMedicine. 2019;40:290\u2013304.","journal-title":"EBioMedicine"},{"issue":"4","key":"1579_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41389-020-0226-z","volume":"9","author":"J Chen","year":"2020","unstructured":"Chen J, et al. ACSL4 promotes hepatocellular carcinoma progression via c-Myc stability mediated by ERK\/FBW7\/c-Myc axis. Oncogenesis. 2020;9(4):42.","journal-title":"Oncogenesis"},{"issue":"6","key":"1579_CR36","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1042\/cs0830639","volume":"83","author":"C Haslett","year":"1992","unstructured":"Haslett C. Resolution of acute inflammation and the role of apoptosis in the tissue fate of granulocytes. Clin Sci (Lond). 1992;83(6):639\u201348.","journal-title":"Clin Sci (Lond)"},{"issue":"3","key":"1579_CR37","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nrc2803","volume":"10","author":"M Kavallaris","year":"2010","unstructured":"Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010;10(3):194\u2013204.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1579_CR38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/1479-7364-2-2-138","volume":"2","author":"V Vasiliou","year":"2005","unstructured":"Vasiliou V, et al. Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Hum Genomics. 2005;2(2):138\u201343.","journal-title":"Hum Genomics"},{"issue":"6","key":"1579_CR39","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.7150\/thno.50571","volume":"11","author":"C Zhang","year":"2021","unstructured":"Zhang C, et al. KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of TRKA independently of its demethylase activity in chronic myelogenous leukemia. Theranostics. 2021;11(6):2691\u2013705.","journal-title":"Theranostics"},{"issue":"3","key":"1579_CR40","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1021\/tx2005184","volume":"25","author":"B Yoval-S\u00e1nchez","year":"2012","unstructured":"Yoval-S\u00e1nchez B, et al. Differences in susceptibility to inactivation of human aldehyde dehydrogenases by lipid peroxidation byproducts. Chem Res Toxicol. 2012;25(3):722\u20139.","journal-title":"Chem Res Toxicol"},{"issue":"2","key":"1579_CR41","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.molmed.2017.12.003","volume":"24","author":"HM Heymann","year":"2018","unstructured":"Heymann HM, et al. Aldehyde-Induced DNA and Protein Adducts as Biomarker Tools for Alcohol Use Disorder. Trends Mol Med. 2018;24(2):144\u201355.","journal-title":"Trends Mol Med"},{"issue":"2","key":"1579_CR42","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/iub.2166","volume":"72","author":"L Chen","year":"2020","unstructured":"Chen L, et al. Silencing transcription factor FOXM1 represses proliferation, migration, and invasion while inducing apoptosis of liver cancer stem cells by regulating the expression of ALDH2. IUBMB Life. 2020;72(2):285\u201395.","journal-title":"IUBMB Life"},{"issue":"6385","key":"1579_CR43","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/358417a0","volume":"358","author":"JM Kyriakis","year":"1992","unstructured":"Kyriakis JM, et al. Raf-1 activates MAP kinase-kinase. Nature. 1992;358(6385):417\u201321.","journal-title":"Nature"},{"issue":"23","key":"1579_CR44","doi-asserted-by":"publisher","first-page":"34395","DOI":"10.18632\/oncotarget.9118","volume":"7","author":"MB Aldonza","year":"2016","unstructured":"Aldonza MB, et al. Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation. Oncotarget. 2016;7(23):34395\u2013419.","journal-title":"Oncotarget"},{"issue":"1","key":"1579_CR45","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1158\/0008-5472.CAN-17-0577","volume":"78","author":"KE Arnst","year":"2018","unstructured":"Arnst KE, et al. A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance. Cancer Res. 2018;78(1):265\u201377.","journal-title":"Cancer Res"},{"issue":"3","key":"1579_CR46","first-page":"3628","volume":"16","author":"XK Zhan","year":"2018","unstructured":"Zhan XK, et al. Betulinic acid exerts potent antitumor effects on paclitaxel-resistant human lung carcinoma cells (H460) via G2\/M phase cell cycle arrest and induction of mitochondrial apoptosis. Oncol Lett. 2018;16(3):3628\u201334.","journal-title":"Oncol Lett"},{"issue":"87","key":"1579_CR47","doi-asserted-by":"publisher","first-page":"15784","DOI":"10.1039\/C5CC06424D","volume":"51","author":"W Heydenreuter","year":"2015","unstructured":"Heydenreuter W, et al. Alkynol natural products target ALDH2 in cancer cells by irreversible binding to the active site. Chem Commun (Camb). 2015;51(87):15784\u20137.","journal-title":"Chem Commun (Camb)"},{"issue":"9","key":"1579_CR48","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1055\/s-0043-109558","volume":"83","author":"ME Issa","year":"2017","unstructured":"Issa ME, et al. Targeting Multiple Myeloma Cancer Stem Cells with Natural Products - Lessons from Other Hematological Malignancies. Planta Med. 2017;83(9):752\u201360.","journal-title":"Planta Med"},{"issue":"4\u20135","key":"1579_CR49","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000468794","volume":"46","author":"A Yoshida","year":"1992","unstructured":"Yoshida A, et al. Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. Enzyme. 1992;46(4\u20135):239\u201344.","journal-title":"Enzyme"},{"key":"1579_CR50","doi-asserted-by":"publisher","first-page":"100770","DOI":"10.1016\/j.drup.2021.100770","volume":"57","author":"L Gao","year":"2021","unstructured":"Gao L, et al. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resist Updat. 2021;57:100770.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"1579_CR51","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.molcel.2010.12.016","volume":"41","author":"D Canzio","year":"2011","unstructured":"Canzio D, et al. Chromodomain-mediated oligomerization of HP1 suggests a nucleosome-bridging mechanism for heterochromatin assembly. Mol Cell. 2011;41(1):67\u201381.","journal-title":"Mol Cell"},{"issue":"3","key":"1579_CR52","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/nchembio.2008","volume":"12","author":"MM M\u00fcller","year":"2016","unstructured":"M\u00fcller MM, et al. A two-state activation mechanism controls the histone methyltransferase Suv39h1. Nat Chem Biol. 2016;12(3):188\u201393.","journal-title":"Nat Chem Biol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-022-01579-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-022-01579-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-022-01579-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T07:04:14Z","timestamp":1651043054000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-022-01579-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1579"],"URL":"https:\/\/doi.org\/10.1186\/s12943-022-01579-9","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,27]]},"assertion":[{"value":"8 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research presented here has been performed in accordance with the Declaration of Helsinki and has been approved by the ethics committee of Shenyang Pharmaceutical University and General Hospital of Central Theater Command of People's Liberation Army.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}